Benzoquinoplatin, an Apurinic/Apyrimidinic site Adduct-Forming Agent, Disables APE1 repair and overcomes cancer chemoresistance
Biochemical Pharmacology · 2026-12 · 254 · 118593
DOI: 10.1016/j.bcp.2026.118593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-12. Verfasst von Jeeyoon Kang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Seoul 04310, the Republic of Korea; Research Institute of Women's Health, Sookmyung Women's University, Seoul 0431…. Hauptthemen laut MEDLINE: DNA-(Apurinic or Apyrimidinic Site) Lyase, Drug Resistance, Neoplasm, Antineoplastic Agents, DNA Repair. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Korea Ministry of Trade Industry and Energy, National Research Foundation of Korea, Korea Drug Development Fund.
Abstract (Originalsprache)
Apurinic/apyrimidinic (AP) sites are abundant but normally short-lived intermediates of base excision repair because they are rapidly processed by AP endonuclease 1 (APE1). Here, we identify benzoquinoplatin (BQP), a benzoquinoline complex with a monofunctional platinum(II) moiety, as an AP-site-directed adduct-former that covalently traps DNA lesions. Following incubation with AP-containing DNA and removal of unbound compound, benzoquinoplatin rendered the lesion refractory to APE1-mediated cleavage, demonstrating that repair was disrupted at the substrate level rather than through direct inhibition of the enzyme. Computational modelling supports a dual mechanism where benzoquinoplatin occupies the AP site and positions Pt for neighbor-base adduct formation. In cancer cells, benzoquinoplatin induced sustained phosphorylated histone H2AX (γH2AX) signalling, cell cycle arrest, apoptosis, and durable suppression of proliferative capacity. Consistent with this mechanism, benzoquinoplatin exhibits markedly enhanced cytotoxic and antiproliferative effects compared with cisplatin in multiple cancer cell lines. Importantly, benzoquinoplatin retains potent activity in cisplatin-resistant cancer cells and effectively suppresses tumor growth in resistant xenograft models in vivo. Furthermore, benzoquinoplatin demonstrates synergistic interactions with poly(ADP-ribose) polymerase (PARP) inhibition, as cooperative disruption of DNA repair pathways amplifies cytotoxic efficacy. Collectively, these findings identify benzoquinoplatin as a DNA repair-interfering platinum agent that induces persistent DNA damage and overcomes cisplatin resistance. This work highlights a strategy for targeting DNA repair intermediates to enhance the efficacy of platinum-based chemotherapy and provides a framework for the development of next-generation platinum therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Seoul 04310, the Republic of Korea; Research Institute of Women's Health, Sookmyung Women's University, Seoul 04310, the Republic of Korea.
- Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, the Republic of Korea.
- Department of Chemistry, Gwangju 61005, the Republic of Korea; Research Center for Innovative Energy and Carbon Optimized Synthesis for Chemicals (Inn-ECOSysChem), Gwangju Institute of Science and Technology, Gwangju 61…
- Department of Biological Sciences, Seoul 04310, the Republic of Korea.
- Department of Chemistry, Gwangju 61005, the Republic of Korea.
- Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, the Republic of Korea. Electronic address: ifglee@kaist.ac.kr.
Förderung
- Korea Ministry of Trade Industry and Energy
- National Research Foundation of Korea
- Korea Drug Development Fund
- Korea Ministry of Education
Zitieren
APA
Kang, J., Kim, S., Heo, D., Kim, J., Choi, D., Park, M., Kim, D., Jung, E., Kim, M. J., Lee, B. C., Park, Y., Jung, D., Seo, J., Lee, G., & Kim, Y. (2026). Benzoquinoplatin, an Apurinic/Apyrimidinic site Adduct-Forming Agent, Disables APE1 repair and overcomes cancer chemoresistance. Biochemical Pharmacology, 254, 118593. https://doi.org/10.1016/j.bcp.2026.118593
Vancouver
Kang J, Kim S, Heo D, Kim J, Choi D, Park M, et al. Benzoquinoplatin, an Apurinic/Apyrimidinic site Adduct-Forming Agent, Disables APE1 repair and overcomes cancer chemoresistance. Biochemical Pharmacology. 2026;254:118593. doi:10.1016/j.bcp.2026.118593
BibTeX
@article{Kang2026,
author = {Kang, Jeeyoon and Kim, Seohyun and Heo, Donguk and Kim, Jongsik and Choi, Daye and Park, Minji and Kim, Dayeon and Jung, Eunyoung and Kim, Myung-Jin and Lee, Byung-Chul and Park, Yehyeong and Jung, Daeun and Seo, Junhyeok and Lee, Gwangrog and Kim, Yonghwan},
title = {Benzoquinoplatin, an Apurinic/Apyrimidinic site Adduct-Forming Agent, Disables APE1 repair and overcomes cancer chemoresistance},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {254},
pages = {118593},
doi = {10.1016/j.bcp.2026.118593}
}
EUVIMED